Table 2.
Design | Extravasation sign | No. contrast-leakage positive (%) | Total number participating | Time-frame | Outcome | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | |
---|---|---|---|---|---|---|---|---|---|---|
In-hospital mortality | ||||||||||
Becker et al. (36) | Retrospective | Contrast extravasation | 52 (46) | 113 | All patients | Hospital fatality | 77 | 73 | 63 | 84 |
Goldstein et al. (37) | Retrospective | Contrast extravasation | 58 (56) | 104 | All patients | Hospital fatality | 73 | 50 | 33 | 85 |
Wada et al. (16) | Retrospective | Spot sign | 13 (33) | 39 | All patients | Hospital fatality | 43 | 69 | 23 | 85 |
Delgado Almandoz et al. (33) | Retrospective | Spot sign | 133 (23) | 573 | All patients | Hospital fatality | 41 | 85 | 56 | 76 |
Li and Wang et al. (21) | Prospective | Spot sign | 30 (22) | 139 | Within 6 h | Hospital fatality | 60 | 81 | 20 | 96 |
Romero et al. (23) | Prospective | Spot sign | 31 (24) | 131 | All patients | Hospital fatality | 68 | 88 | 61 | 91 |
Rizos et al. (22) | Prospective | Spot sign | 27 (27) | 101 | Within 6 h | Hospital fatality | 47 | 77 | 26 | 89 |
90-days mortality | ||||||||||
Li and Wang et al. (21) | Prospective | Spot sign | 30 (22) | 139 | Within 6 h | Case fatality | 50 | 82 | 27 | 93 |
Demchuk et al. (18) | Prospective | Spot sign | 53 (25) | 211 | Within 6 h | Case fatality | 43 | 81 | 43 | 80 |
Rizos et al. (22) | Prospective | Spot sign | 27 (27) | 101 | Within 6 h | Case fatality | 29 | 74 | 26 | 77 |
90-days outcome | ||||||||||
Delgado-Almandoz et al. (33) | Retrospective | Spot sign | 133 (23) | 573 | All patients | mRS > 3a | 23 | 89 | 51 | 70 |
Li and Wang et al. (21) | Prospective | Spot sign | 30 (22) | 139 | Within 6 h | mRS > 2 | 36 | 94 | 87 | 58 |
Romero et al. (23) | Prospective | Spot sign | 31 (24) | 131 | Within 24 h | mRS > 3a | 34 | 94 | 90 | 50 |
Havsteen and Ovesen et al. (38) | Prospective | Spot sign | 37 (29) | 128 | Within 4.5 h | mRS > 4 | 60 | 86 | 68 | 81 |
aBased on the surviving patients at 3 months.